Gansu Ascentage Academy of Sciences

Ascentage Pharma is a global clinical-stage biotechnology company dedicated to developing first-in-class and best-in-class therapies for cancers, hepatitis B virus (HBV), and age-related diseases. Headquartered in Suzhou, China, the company leverages its proprietary protein-protein interaction (PPI) drug discovery platform to target key pathways in apoptosis, such as BCL-2, IAP, and MDM2-p53. Its lead asset, olverembatinib (HQP1351), is a third-generation BCR-ABL inhibitor that is commercially available in China for patients with drug-resistant chronic myeloid leukemia. Ascentage's robust pipeline includes several late-stage candidates, most notably the BCL-2 inhibitor lisaftoclax (APG-2575), which is undergoing global Phase 3 trials. The company maintains a strong international presence with R&D centers and clinical operations in China, the United States, and Australia.